{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5FU&page=6",
    "query": {
      "intervention": "5FU",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1032,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5FU&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5FU&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T12:50:19.810Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01434069",
      "title": "Phase I Trial of Combination of FOLFIRI and SOM 230",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Tumor"
      ],
      "interventions": [
        {
          "name": "SOM230C LAR",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2011-09",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-24",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434069"
    },
    {
      "nct_id": "NCT03343301",
      "title": "A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Cancer",
        "Gastrointestinal Cancer Metastatic",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Bemarituzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Modified FOLFOX6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Five Prime Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-11-30",
      "completion_date": "2019-01-31",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 7,
      "location_summary": "Tucson, Arizona • Greenbrae, California • Whittier, California + 4 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03343301"
    },
    {
      "nct_id": "NCT02715531",
      "title": "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 243,
      "start_date": "2016-04-06",
      "completion_date": "2021-05-31",
      "has_results": false,
      "last_update_posted_date": "2021-07-09",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 12,
      "location_summary": "Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715531"
    },
    {
      "nct_id": "NCT05203172",
      "title": "The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2022-07-05",
      "completion_date": "2032-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05203172"
    },
    {
      "nct_id": "NCT04731467",
      "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Papillary Thyroid Cancer",
        "Melanoma",
        "Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "CM-24 and Nivolumab - Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion",
          "type": "DRUG"
        },
        {
          "name": "CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab, Nab paclitaxel and Gemcitabine - Expansion",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab and Nal-IRI/5-FU/LV - Expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Famewave Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2021-03-19",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04731467"
    },
    {
      "nct_id": "NCT04847063",
      "title": "Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peritoneal Mesothelioma",
        "Peritoneal Carcinomatosis",
        "Ovarian Cancer",
        "Gastrointestinal Cancer",
        "Appendiceal Cancer",
        "Atypical Mesothelial Proliferation",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Sodium Thiosulfate",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Hyperthermic Intraperitonial Chemotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Mitomycin C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-10-19",
      "completion_date": "2034-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04847063"
    },
    {
      "nct_id": "NCT00942266",
      "title": "Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Colon",
        "Adenocarcinoma of the Rectum",
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2009-07",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-06-23",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00942266"
    },
    {
      "nct_id": "NCT01489865",
      "title": "ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ABT-888",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX-6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2011-01-03",
      "completion_date": "2023-12-07",
      "has_results": true,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489865"
    },
    {
      "nct_id": "NCT05863195",
      "title": "Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Colorectal Carcinoma",
        "Metastatic Malignant Neoplasm in the Liver",
        "Stage IV Colorectal Cancer AJCC v8",
        "Unresectable Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Floxuridine",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Implantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Intrahepatic Infusion Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Panitumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single Photon Emission Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 408,
      "start_date": "2024-04-10",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05863195"
    },
    {
      "nct_id": "NCT00006037",
      "title": "Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "oglufanide disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "1999-11",
      "completion_date": "2001-11",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-10-18T12:50:19.810Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006037"
    }
  ]
}